McLaren Racing will work with Sanofi’s Industrial Affairs team to achieve expertise in the production industry, allowing Sanofi to meet patients’ needs from around the world by making better use of its worldwide network and supporting the supply of its broad portfolio.
McLaren Racing will bring its digital and analytical skillset to help Sanofi teams focus on major items impacting performance, and better anticipate and rectify them, through its bespoke Accelerator programme, which focuses F1 ingenuity on industrial challenges. Loss analysis, modelling and simulation of manufacturing line scheduling, and, in particular, product change-overs will be critical areas for enhancing performance at Sanofi manufacturing sites. Performance-driven data can be translated into the culture and thinking of partners via joint work through McLaren Accelerator, leaving a lasting legacy.
McLaren has a history of success in maximising asset performance in a competitive, high-pressure environment in order to bring speed and acceleration to change. This was apparent during the covid-19 pandemic, when, as part of a UK industry consortium, McLaren Group accelerated ventilator production from 20 per week to 400 per day by using data to support decision insights and laying the groundwork for operational excellence.
Aside from F1’s technical leadership, the partnership will place a special emphasis on the people dimension of high performance. The collaboration will bring a racing attitude, imitating the competitive, fast-paced environment of F1 to help accelerate improvements, learnings, and sharing of best practices across sites, cultivating a “one Sanofi spirit.” This one-of-a-kind opportunity will match the strengths of both companies with the speed, agility, teamwork, and consistent progress required to succeed in both motorsport and healthcare discoveries.
Zak Brown, CEO, McLaren Racing, said, “We are delighted to be partnering with Sanofi. It is an important opportunity for two global brands who share values to work together to maximise performance through our bespoke Accelerator programme. We look forward to continuing to collaborate with Sanofi to make a positive impact not only in manufacturing but to help Sanofi improve patients’ lives.”
Paul Hudson, CEO, Sanofi, commented, “We are thrilled to partner with McLaren and learn from their winning spirit and culture of going over and above. I see a lot of commonalities in our shared values to stretch, with courage and determination, so we can maximize performance and operational excellence. We want to run our lines with the speed, precision and efficiency of an F1 racing team.”